Release Date: 12 July 2024
Bispecific antibodies hold immense promise for treating autoimmune and inflammatory diseases, despite none being approved to date. With their ability to precisely target aberrant immune responses while sparing healthy tis...
Release Date: 12 July 2024
Hemlibra, a breakthrough bispecific antibody developed by Roche, continues to assert dominance in the bispecific antibodies market, contributing significantly to overall sales. Its unparalleled efficacy in treating hemoph...
Release Date: 12 July 2024
Vabysmo stands as a pioneering milestone in ophthalmology as the first and only bispecific antibody tailored for eye conditions. Developed to address unmet needs in ocular disorders, Vabysmo offers a novel therapeutic app...
Release Date: 12 July 2024
Rybrevant marks a groundbreaking advancement as the first bispecific antibody approved for a solid cancer indication. Its approval in May 2021 for non-small cell lung cancer underscores its significance in addressing unme...
Release Date: 12 July 2024
Cadonilimab, a pioneering achievement by Akeso, marks a milestone as the first bispecific antibody targeting two pivotal immune checkpoints: PD-1 and CTLA-4. Approved in China, it heralds a new era in in cancer immunother...
Release Date: 12 July 2024
Blincyto, the pioneering bispecific antibody, made history as the first of its kind to receive FDA approval, revolutionizing cancer treatment. Its innovative mechanism of action, engaging T cells to target cancer cells, p...
Release Date: 12 July 2024
Commercially, bispecific antibodies represent a lucrative opportunity in the pharmaceutical market. Their unique mechanism of action and potential to target multiple disease pathways make them attractive candidates for ph...
Release Date: 12 July 2024
Bispecific antibodies are increasingly utilized in combination treatments, leveraging their unique mechanisms of action to enhance therapeutic efficacy across a spectrum of diseases. By targeting multiple pathways simultaneously, bispecific antibodie...
Release Date: 12 July 2024
Bispecific antibodies are increasingly integrated into combination therapies with targeted therapy, offering a synergistic approach to precision medicine. By simultaneously targeting specific antigens and pathways, bispec...
Release Date: 12 July 2024
The combination of bispecific antibodies with radiation therapy or chemoradiation presents a promising strategy in cancer treatment, capitalizing on synergistic effects to enhance tumor control and improve patient outcome...
Release Date: 12 July 2024
Bispecific antibodies hold immense potential in combination with immunotherapy, revolutionizing cancer treatment paradigms. By engaging immune cells and tumor antigens simultaneously, they enhance immune responses and ove...
Release Date: 12 July 2024
Bispecific antibodies, in tandem with chemotherapy, represent a promising frontier in cancer treatment. The ability to simultaneously target tumor cells and engage the immune system compliments the cytotoxic actions of ch...
Release Date: 12 July 2024
Bispecific antibodies, a promising class of immunotherapeutics, bind to two different antigens simultaneously, enhancing their specificity and efficacy. They offer diverse therapeutic strategies, including redirecting imm...
Release Date: 12 July 2024
Twelve bispecific antibodies have garnered regulatory approved, with an additional four under review, signaling a growing recognition of their therapeutic potential. The majority of these approvals are allocated to oncolo...
Release Date: 12 July 2024
Zanidatamab represents a pioneering breakthrough in cancer therapy as the first-in-class HER2 x HER2 bispecific developed by Zymeworks. Targeting non-overlapping regions of HER2, this innovative antibody offer a novel app...